Navigation Links
Kidney disease worsens in a fourth of African-Americans despite therapy for hypertension
Date:5/5/2008

The best available treatment for chronic kidney disease from high blood pressure did not keep the disease from substantially worsening in about a fourth of African-Americans studied, according to long-term results of a National Institutes of Health study published April 28, 2008, in the Archives of Internal Medicine.

The largest and longest study of chronic kidney disease in African-Americans the African American Study of Kidney Disease and Hypertension (AASK) found that the disease substantially worsened in about one-fourth of participants, even with very good blood pressure control and use of kidney-protecting medications, currently the best available treatment. This subgroup of patients either lost half their kidney function or reached kidney failure, also known as end-stage renal disease.

"Despite these sobering results, blood pressure control is still vital in kidney disease and in many other diseases," said NIH Director Elias A. Zerhouni, M.D. "But this research clearly signals the importance of preventing kidney disease, better understanding causes and finding better ways to manage it in the 26 million Americans who already have it."

Good news also emerged from the study. About one-third of participants experienced a slow decline in kidney function, about what is generally observed with aging. "The factors that may be responsible for such a small loss of kidney function need to be studied," said Lawrence Y. Agodoa, M.D., senior author of the study and director of kidney failure research at NIHs National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which funded the study.

The AASK Cohort Study observed about 750 African-Americans on recommended therapy for chronic kidney disease from 2002 to 2007. Study participants were initially recruited beginning in 1995 for the AASK Clinical Trial www.nih.gov/news/pr/nov2002/niddk-25.htm, which concluded in 2001 that an ACE inhibitor medication protected the kidneys better than two other classes of blood pressure drugs. During the Cohort Study, nearly 9 out of 10 participants were taking an ACE inhibitor or an angiotensin receptor blocking drug, and average blood pressure was 133/78 mmHg, close to national guidelines for high blood pressure in people with chronic kidney disease.

Uncontrolled high blood pressure, an increase in the number of people with diabetes, and the aging of the U.S. population means more people than ever are getting and living with kidney problems. About 13 percent of the U.S. population, up from 10 percent in 1994, now have chronic kidney disease. And in 2005, more than 485,000 people were on chronic dialysis or had a kidney transplant for kidney failure, costing Medicare, private insurers and patients $32 billion.


'/>"/>

Contact: Mary Harris
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Related medicine news :

1. Major League Baseball Hall of Famer Don Sutton Helps Kidney Cancer Patients Stay In The Game(TM)
2. 3 Women Suffer Kidney Failure After Derriere Injections
3. Bioartificial Kidney Cuts Death Risk, Improves Outcomes
4. Kidney Care Community Applauds National Taxpayers Unions Endorsement of Medicare Reforms to Extend Patient Private Health Insurance Coverage; Calls Proposal Common Sense Coverage Reform
5. Cutting Phosphate May Protect Kidney Patients From Heart Trouble
6. Muscle Mass May Not Explain High Creatinine in Black Kidney Patients
7. Readily available treatment could help prevent heart disease in kidney patients
8. Study Points to New Treatments for Polycystic Kidney Disease
9. Raloxifene Safe for Women With Decreased Kidney Function
10. Kidney cancer deaths show overall decrease in Europe
11. Diplomat Specialty Pharmacy Hires National Accounts Director To Expand Kidney Disease Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... As part ... two webinars in February 2016. Each webinar features a dynamic expert and thoughtful ... benefit their athletes, patients and facilities. Both events are free to attend, but ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is ... leading bottled water brand owners that topped the list as a result of their ... conversion. The premier brand was Tibet 5100, a top notch water company that specializes ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... Ongoing ... the Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer ... experts released today illustrates the prevalence and causes of TBI among the aging population, ...
(Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LOS ANGELES , Feb. 10, 2016  Oxis ... blood cancer drug, OXS-1550, was described as a "clinical ... with the drug went into complete cancer remission. ... the University of Minnesota Masonic Cancer Center. ... the University of Minnesota Masonic Cancer Center. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... and OR AKIVA, Israel ... Regentis Biomaterials Ltd., a leader in the field ... D investment round on February 5, 2016. The $15 ... ("Haisco"), a leading Chinese pharmaceutical manufacturer, and was ... Vitalife Partners, Generali Financial Holdings and both the Technion ...
Breaking Medicine Technology: